Leadership
Curogen CEO shares what’s behind keen global investor interest in Korean venture's latest financing round and what differentiates its next-generation autoimmune disease and dermatology assets.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Recent moves in the industry include changes at the top at Mestag Therapeutics, Atossa Therapeutics and Kaida BioPharma, plus Alchemab Therapeutics gets a new CBO from Sanofi.
Lupin’s CEO Vinita Gupta and MD Nilesh Gupta outline the company’s innovation agenda, strategy on GLP-1 drugs including fortnightly candidate bofanglutide, plans to get to number one in the domestic market and the legacy of their father in this podcast interview.
CEO Matt Gline talked to Scrip about preparing for the launch of brepocitinib in dermatomyositis, lessons learned from Vtama, and how smaller biopharmas are delivering launch successes.
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
Activist investor and board chair Peter Tang takes on CEO role at Aurinia, while the COO, CMO and CFO also were replaced.
Recent moves in the industry include C-suite changes at BiomX and Novelty Nobility, plus Novartis gets a new board member.
As the Danish vaccine maker plots further M&A activity.
Recent moves in the industry include C-suite changes at Syntis Bio, Inimmune and Epigenic Therapeutics, plus Seres Therapeutics gets a new interim CEO from Merck & Co.
In an interview with Scrip, Samsung Bioepis’ VP and Innovation Project Lead talks about the newly launched innovation project as well as the firm's strategies and goals in ADCs and other novel therapeutics.
As the Belgian firm's blockbuster beats AbbVie's Skyrizi in a head-to-head psoriatic arthritis study.
Recent moves in the industry include changes at the top at Merck & Co., Daiichi Sankyo and Amber Therapeutics, plus Merck & Co. gets a new senior executive from Sanofi.
Garijo’s exit comes at a time when Merck gets set to navigate some key headwinds, but without its outgoing chief and her experience in portfolio‑streamlining and targeted acquisitions.
AbbVie chief scientific officer Thakkar talked about ways to avoid pitfalls in immunology studies, while Neurocrine chief scientific officer Onyia outlined the company’s new obesity strategy, among other updates.
Parexel’s CEO Peyton Howell and India chief Sanjay Vyas talked to Scrip about trials amid global upheavals, the slowdown in big pharma decision-making and pivot in some cases to the FSP model, an evolving DCT definition and India opportunities.
A new wave of commercial-stage biopharmas are interested in launching drugs in Europe but weighing risks related to US drug pricing policies
The Swiss major's immunology chief Angelika Jahreis tells Scrip of her high hopes for the potential pipeline-in-a-product.
CRDMOs must embrace AI to keep pace with big pharma partners - but what is expected of them, which data can they use, where are Indian firms on the adoption curve and does the ‘China Plus One’ business proposition still hold? Leaders discussed these topics at BioAsia.